Alliancebernstein L.P. Purchases 53,325 Shares of Icon Plc $ICLR

Alliancebernstein L.P. lifted its position in Icon Plc (NASDAQ:ICLR) by 4.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,374,074 shares of the medical research company’s stock after acquiring an additional 53,325 shares during the period. Alliancebernstein L.P. owned 1.70% of Icon worth $240,463,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ICLR. Private Trust Co. NA raised its stake in shares of Icon by 200.0% in the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after purchasing an additional 94 shares during the last quarter. Ameriflex Group Inc. purchased a new position in Icon during the third quarter valued at $33,000. Wilmington Savings Fund Society FSB increased its holdings in Icon by 153.4% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 201 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Icon in the third quarter worth about $63,000. Finally, Johnson Financial Group Inc. bought a new stake in Icon in the third quarter worth $71,000. 95.61% of the stock is currently owned by institutional investors.

Icon Price Performance

Shares of NASDAQ ICLR opened at $98.33 on Monday. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00. The business’s 50 day moving average price is $144.09 and its 200 day moving average price is $165.40. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market cap of $7.94 billion, a P/E ratio of 13.31, a P/E/G ratio of 2.52 and a beta of 1.36.

Analyst Ratings Changes

ICLR has been the topic of a number of recent research reports. Leerink Partners restated a “market perform” rating and set a $105.00 price objective on shares of Icon in a research report on Thursday, February 12th. Bank of America reissued an “underperform” rating and set a $75.00 target price on shares of Icon in a research report on Thursday, February 12th. Zacks Research lowered Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and cut their price target for the stock from $183.00 to $120.00 in a report on Wednesday, February 18th. Finally, Citigroup dropped their price target on Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Six investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Icon presently has an average rating of “Hold” and a consensus target price of $146.80.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.